A defining characteristic of the solid TME is profound hypoxia—an oxygen-deprived milieu that has been implicated in metabolic dysfunction and immune exhaustion of T cells. Experimental findings illustrate that under hypoxic conditions, CAR T cells rapidly diminish their effector capabilities while upregulating inhibitory receptors such as PD-1 and TIM-3, hallmarks of T cell exhaustion. This metabolic constraint coupled with intense immunosuppressive signaling compounds the difficulty of achieving durable tumor control.

Beyond hypoxia, the immune landscape of solid tumors is dominated by suppressive myeloid populations, including myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs). These cell types secrete inhibitory cytokines such as TGF-β and IL-10, which blunt cytotoxic T cell function. Furthermore, they manipulate the metabolic competition within the tumor niche by depleting essential nutrients like arginine and glucose, effectively starving T cells of critical resources necessary for their proliferation and persistence. This metabolic tug-of-war epitomizes the sophisticated tumor strategies to evade immunologic eradication.

Physical barriers imposed by the dense extracellular matrix and chaotic vasculature further restrict immune effector trafficking into the tumor core. Preclinical orthotopic models, notably in pancreatic and gastric cancers, demonstrate that CAR T cells preferentially accumulate at the tumor periphery, rarely infiltrating the densely packed core regions where malignant cells reside. This uneven distribution results in incomplete and heterogeneous tumor killing, thereby undermining the overall efficacy of the treatment. Coupled with this is the challenge of limited CAR T cell persistence in vivo: rapid expansion is often followed by contraction and eventual disappearance from circulation, paralleling tumor relapse and disease progression.

Another persistent challenge is antigen heterogeneity and specificity within solid tumors. Tumor-associated antigens like Claudin-18.2 and mesothelin, while promising targets, exhibit heterogeneous expression across cancer cell populations. This leads to selective pressure favoring antigen-negative clones, which expand and contribute to tumor escape. Moreover, many of these antigens are expressed at low levels in normal tissues, risking off-tumor, on-target toxicity. Clinical data from phase II trials targeting Claudin-18.2 vividly highlight this risk, showing significant gastric mucosal damage in a notable fraction of patients, underscoring the difficulty in identifying truly tumor-exclusive targets.

Adaptive immune resistance further complicates treatment outcomes. Tumors frequently evolve under immune pressure by altering antigen presentation pathways, enabling them to evade recognition and destruction by therapeutic T cells. The role of endogenous T cells in preventing antigen-loss mediated escape is increasingly clear, suggesting that single-antigen targeted therapies may be insufficient in isolation. Cytokine responses in the TME, particularly involving interferon-gamma (IFN-γ), embody a paradoxical role: while IFN-γ can enhance immune activation, it also induces immunosuppressive PD-L1 expression within the tumor, fostering a feedback loop of adaptive inhibition. This biological insight paves the way for rational combination therapies integrating immune checkpoint blockade with adoptive cell therapies.

Safety concerns remain a critical barrier to the broader application of ACT and ICEs in solid tumors. Cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) are predominant adverse events arising from these therapies. These syndromes represent hyperinflammatory states driven by exuberant activation of immune effectors post-infusion, rather than mere dose-dependent toxicities. Their incidence correlates with tumor burden and baseline patient inflammatory milieu. Recent clinical trials of Claudin-18.2 CAR T cells report very high rates of CRS—exceeding 95%—although mostly mild-to-moderate in severity. BiTEs such as tarlatamab also induce substantial CRS rates, necessitating cautious dose escalation and inpatient monitoring protocols.

ICANS, while less frequent than CRS, poses significant clinical challenges due to its unpredictable neurological manifestations, including encephalopathy and seizures. Management often requires high-dose corticosteroids and temporarily halting therapy, complicating trial design and clinical management. Additionally, high-dose interleukin-2 (IL-2) administration following tumor-infiltrating lymphocytes (TIL) infusion triggers capillary leak syndrome (CLS), characterized by vascular permeability and hypotension, underscoring the delicate balance between therapeutic intensity and tolerability in ACT trials.

Compounding these acute toxicities is the emerging recognition of immune effector cell–associated hemophagocytic lymphohistiocytosis–like syndrome (IEC-HS), a severe hyperinflammatory condition marked by cytopenias, coagulopathy, and multiorgan dysfunction, often manifesting during the resolution phase of CRS. Its management frequently necessitates intensified immunosuppressive strategies, including high-dose steroids alongside agents such as anakinra and ruxolitinib. The acknowledgment of IEC-HS as a discrete clinical entity has informed evolving toxicity mitigation frameworks, aiming to maximize therapeutic benefit while minimizing life-threatening adverse events.

The innovation in immunotherapy has been paralleled by the development of strategies to mitigate these toxicities. Step-up dosing regimens for T cell engagers and selective corticosteroid prophylaxis in high-risk cohorts are becoming integral components of clinical protocols, striving to strike a balance between efficacy and safety. These approaches reflect an increasingly nuanced understanding of the inflammatory cascades unleashed by immune therapies and a commitment to enhancing patient outcomes.

Manufacturing complexities add another dimension to the challenges faced in solid tumor immunotherapy. Adoptive cell therapy often involves labor-intensive, patient-specific processes of T cell isolation, genetic modification, expansion, and quality control. Variability in expansion potential attributable to individual donor variability and T cell fitness foreshadows significant scalability and cost hurdles. Clinical translation will necessitate innovations in manufacturing to enable broad accessibility and economic viability.

As research advances, it becomes clear that overcoming the solid tumor microenvironment’s multifactorial resistance mechanisms demands multidimensional approaches. Incorporating metabolic reprogramming, improving trafficking, selecting optimal antigen targets, and developing robust combinatorial regimens including checkpoint inhibitors are essential. Equally important is refining dosing paradigms and supportive care to mitigate toxicities without blunting therapeutic efficacy.

In summary, while adoptive cell therapies and immune cell engagers have revolutionized hematologic cancer treatment, their application in solid tumors remains beset by formidable biological barriers and safety concerns. Progress hinges on a deep mechanistic understanding of the tumor microenvironment and immune dynamics, alongside innovative clinical strategies to enhance trafficking, persistence, and antigen specificity. Coupled with careful toxicity management and manufacturing advancements, these efforts are poised to unlock the full potential of immunotherapy for patients battling solid malignancies.

The emerging paradigm underscores the essential interplay between tumor biology, immune evasion, and therapeutic design. By unraveling these complex interactions and tailoring interventions accordingly, the field stands on the threshold of transforming the landscape of solid tumor cancer therapy, offering renewed hope for durable remission and improved survival outcomes.

Subject of Research: Advances in cancer immunotherapy focusing on adoptive cell therapy and immune cell engagers for solid tumors.

Article Title: Advances in cancer immunotherapy: adoptive cell therapy and immune cell engagers in solid tumours.

Article References:
Panasci, J., Park, C.L., Tran, B. et al. Advances in cancer immunotherapy: adoptive cell therapy and immune cell engagers in solid tumours. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03450-w

Image Credits: AI Generated

DOI: 27 April 2026

The significance of understanding the microsatellite instability-high variant of colorectal cancer cannot be overstated. This variant often indicates a specific genetic backdrop associated with high levels of mutation and a unique immune landscape. MSI-H colorectal cancers respond differently to treatments, particularly immune checkpoint inhibitors. Understanding the molecular mechanisms driving their behavior is crucial for developing more targeted therapies that can improve patient outcomes. The work presented by Zhang et al. expands our knowledge of this tumor type and introduces MNDA as a potential therapeutic target, revolutionizing how we approach MSI-H colorectal cancer.

As the authors unraveled the connection between MNDA and PMN-MDSC infiltration, they highlighted the role of H3K18 lactylation in this process. Histone lactylation is an epigenetic modification that fuels cancer progression and immune evasion. Prior to this study, histone modifications were largely understood in the context of DNA transcription regulation; however, this research positions lactylation as a key mediator of immune cell behavior. By modifying the chromatin landscape, H3K18 lactylation enables more favorable conditions for PMN-MDSCs to infiltrate tumor microenvironments, leading to significant immunosuppressive effects that enable cancer cells to survive and proliferate unchecked.

The implications of these findings are multi-fold. Firstly, the study raises a crucial question: how do we strategically inhibit the actions of MNDA or counteract its effects on PMN-MDSC infiltration? Targeting this pathway could mitigate the immunosuppressive environment that characterizes MSI-H colorectal cancer. Theoretically, inhibiting MNDA could promote the re-establishment of a more anti-tumor immune environment, paving the way for improved therapeutic responses—particularly with newer immunotherapy agents that aim to unleash the body’s immune system against tumors.

Developments in immunotherapy have already transformed the treatment landscape for various cancers, but MSI-H colorectal cancer remains challenging. Identifying the underlying mechanisms that foster cancer immune escape like those revealed in this study is vital for advancing treatment strategies. The interplay between MNDA and myeloid-derived suppressor cells draws attention not only to the tumor cells themselves but to their interactions with the surrounding immune cells, suggesting a more holistic approach to cancer treatment and prevention.

The research methodology employed by Zhang et al. is commendable, as the authors utilized sophisticated assays to dissect the molecular underpinnings governing the MNDA-PMN-MDSC relationship. The study included in vitro and in vivo experiments designed to elucidate how high levels of MNDA correlate with increased PMN-MDSC activity, supporting the hypothesis that MNDA functions as a facilitator of immunosuppression through epigenetic modification.

Incorporating patient-derived samples into their investigation, the researchers corroborated their findings with clinical relevance, establishing a connection between the laboratory results and real-world patient data. It’s exceptionally noteworthy how the integration of clinical samples enriches the translational potential of such studies, as it draws a clearer line from basic research to applicable therapies. This is precisely the type of research that holds promise in translating innovative findings into actionable strategies for clinical practice.

Additionally, the study opens up avenues for further research into the roles of various histone modifications in the tumor immunity landscape. Given the significance of H3K18 lactylation demonstrated in this work, subsequent studies may want to explore whether other lactylation marks play similar or complementary roles in immune response regulation. The potential for novel therapeutic interventions targeting histone modifications or MNDA presents a tantalizing frontier in cancer therapy.

Moreover, this study also brings various epigenetic changes into the conversation surrounding cancer treatment. As we have come to better understand the complexity of cancer as a disease driven by genetic and epigenetic factors, the role of modifications like H3K18 lactylation will likely become essential components in the future of precision oncology. A multi-targeted approach that encompasses not just genetic alterations but also epigenetic landscapes could yield meaningful improvements in the management of MSI-H colorectal cancer.

In the realm of colorectal cancer treatment, immunotherapy has shown promise, particularly as researchers refine strategies to exploit the unique immune response elicited by tumors. The unveiling of MNDA as a critical player in the immune-suppressive nature of MSI-H colorectal cancer could lead to the development of combination therapies, harmonizing traditional chemotherapy, newer targeted agents, and modulations of the immune response to provoke a stronger anti-cancer effect.

In conclusion, the research conducted by Zhang et al. is timely and vital in our quest to combat MSI-H colorectal cancer. By providing insights into the role of MNDA and PMN-MDSCs, the authors lay the groundwork for future explorations of innovative therapies designed to reverse immune suppression. Their work is expected to resonate deeply within the scientific community and encourage continued investigation into epigenetic mechanisms as potential therapeutic targets. Ultimately, such strides in our understanding of cancer biology hold hope for enhancing patient outcomes in the ever-evolving landscape of cancer treatment.

As the medical community digests these findings, the challenge remains: How can we effectively leverage this newfound knowledge to evolve treatment paradigms and craft regimens that meaningfully disrupt the immunosuppressive state of MSI-H colorectal cancers? The steps forward are filled with promise, urging researchers and clinicians alike to pursue these tantalizing possibilities with vigor and creativity.

Subject of Research: Immunosuppression in microsatellite instability-high colorectal cancer through MNDA and PMN-MDSC infiltration.

Article Title: MNDA promotes immunosuppression in microsatellite instability-high colorectal cancer by facilitating PMN-MDSC infiltration via H3K18 lactylation.

Article References:

Zhang, X., Wang, Wb., Cai, XY. et al. MNDA promotes immunosuppression in microsatellite instability-high colorectal cancer by facilitating PMN-MDSC infiltration via H3K18 lactylation.
J Transl Med 23, 1049 (2025). https://doi.org/10.1186/s12967-025-07097-8

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07097-8

Keywords: MSI-H colorectal cancer, MNDA, PMN-MDSC, immunosuppression, H3K18 lactylation, epigenetics, immunotherapy.

Chronic myeloid leukemia is a type of cancer that originates in the blood-forming cells of the bone marrow and leads to the overproduction of myeloid cells. A hallmark feature of CML is the presence of a specific genetic mutation known as the Philadelphia chromosome, which produces the BCR-ABL fusion protein. This alteration is instrumental in the disease’s pathogenesis, but it is the tumor microenvironment, composed of various immune cells, that plays a critical role in disease progression and therapeutic resistance.

MDSCs are a heterogeneous population of immune cells that typically expand in response to tumor presence. Their primary function is to downregulate immune responses, thus enabling tumors to escape immune surveillance. In the case of CML, the expansion of MDSCs has been linked to poor prognosis and disease progression. They exert their immunosuppressive effects through various mechanisms, including the production of reactive oxygen species and inhibitory cytokines, which can directly impair T-cell activation and function.

The latest findings from Meng and colleagues indicate that MDSCs in CML may also influence the therapeutic response to tyrosine kinase inhibitors (TKIs), the primary treatment for CML. These inhibitors target the BCR-ABL protein, but their effectiveness can be undermined by the presence of MDSCs. The work underlines the necessity of considering immune components when developing treatment protocols for cancer patients, especially those with CML.

Furthermore, the research highlights a bidirectional relationship between MDSCs and the tumor microenvironment. On one hand, tumors recruit MDSCs through the release of various factors; on the other hand, MDSCs can affect the composition and functionality of the tumor microenvironment. This interconnectedness suggests that targeting MDSCs could potentially enhance the effectiveness of existing cancer therapies, providing a multifaceted approach to treatment.

Notably, the study identifies specific markers that can be used to characterize MDSCs in CML patients. These markers may serve as potential therapeutic targets or prognostic indicators. By understanding the unique profile of MDSCs in CML, researchers can devise strategies to either inhibit their suppressive functions or modulate their recruitment to enhance T-cell responses against the leukemia.

The concept of reprogramming the immune landscape is gaining traction in oncology. The implication of Meng et al.’s findings is that it may be possible to convert MDSCs from a hindrance to an asset in the fight against cancer. By employing agents that can turn immune suppression into immune activation, researchers aim to devise novel immunotherapies. Such strategies could create a synergistic effect when combined with traditional and targeted therapies.

Clinical trials will be essential to validate the findings presented in this latest research. Investigating how alterations in MDSC populations correlate with treatment responses will provide critical insights into patient management in CML. Moreover, establishing the therapeutic potential of MDSC modulation could revolutionize treatment protocols and lead to better outcomes in patients who are resistant to current standard-of-care therapies.

Beyond the immediate implications for CML, the insights derived from this study may have broader applications in other malignancies as well. Similar immunosuppressive mechanisms are often at play in various cancers, suggesting potential paradigms that could extend to a wider array of hematologic and solid tumors. The ability to modulate the immune response through targeting MDSCs presents an exciting frontier in cancer research.

As our understanding of the immune system’s role in cancer deepens, therapeutic paradigms continue to evolve. The challenge lies in fine-tuning these approaches to achieve maximal efficacy while minimizing adverse effects. Integrating findings from studies such as those of Meng et al. into clinical practice will require collaboration among researchers, clinicians, and patients alike.

Ultimately, the work of Meng and colleagues serves as a critical reminder of the need for a comprehensive understanding of the tumor environment and immune interactions in shaping the outcomes of cancer therapies. The pursuit of innovative treatments that harness the natural complexities of the immune system holds the promise of not only improving the lives of CML patients but potentially transforming cancer care on a global scale.

With these fundamental insights into the role of MDSCs, we stand at the threshold of a new dawn in cancer therapy. As the journey continues, ongoing research will be essential in further unraveling the intricate dance between cancer cells and the immune system, illuminating strategies to turn the tide in favor of the patient.

In summary, the study conducted by Meng et al. serves as a pivotal reference that advances our understanding of MDSCs in CML. As future research builds upon these findings, we may well witness a paradigm shift in how chronic myeloid leukemia is treated, emphasizing the importance of immune modulation in conjunction with existing therapies.

Subject of Research: Myeloid-derived suppressor cells in chronic myeloid leukemia

Article Title: Advancing our understanding of the influence of myeloid-derived suppressor cells in chronic myeloid leukemia

Article References:

Meng, X., Zhang, Y., Xu, H. et al. Advancing our understanding of the influence of myeloid-derived suppressor cells in chronic myeloid leukemia.
J Cancer Res Clin Oncol 151, 263 (2025). https://doi.org/10.1007/s00432-025-06315-6

Image Credits: AI Generated

DOI: 10.1007/s00432-025-06315-6

Keywords: Myeloid-derived suppressor cells, chronic myeloid leukemia, immune modulation, cancer therapy, tyrosine kinase inhibitors.